Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ardmore Shipping Corporation engages in the seaborne transportation of petroleum products and chemicals worldwide. As of February 15, 2022, the company operated a fleet of 25 double-hulled product and chemical tankers. It serves oil majors, oil companies, oil and chemical traders, chemical companies, and pooling service providers. The company was founded in 2010 and is based in Pembroke, Bermuda.

Ardmore Shipping Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-    THE COMBINATION OF ASC47 LOW DOSE WITH TIRZEPATIDE IN DIET-INDUCED OBESE (DIO) MICE RESULTED IN AN 87% GREATER REDUCTION IN BODY WEIGHT COMPARED TO TIRZEPATIDE MONOTHERAPY. -     ASC47 LOW DOSE IN COMBINATION WITH TIRZEPATIDE DEMONSTRATED STATISTICALLY SIGNIFICANTLY GREATER INCREASE IN EFFICACY THAN ASC47 LOW DOSE IN COMBINATION WITH SEMAGLUTIDE, 87% VS 55%, RESPECTIVELY, IN THE DIO MOUSE MODEL.

ASCLETIS ANNOUNCES ASC47, A MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR TREATMENT OF OBESITY, DEMONSTRATED GREATER EFFICACY WITH TIRZEPATIDE THAN SEMAGLUTIDE IN A PRECLINICAL MODEL

HAMILTON, BERMUDA , JULY 30, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE", THE "COMPANY" OR "WE") TODAY ANNOUNCED RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025. HIGHLIGHTS AND RECENT ACTIVITY REPORTED ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $9.0 MILLION FOR THE THREE MONTHS ENDED JUNE 30, 2025, OR $0.22 EARNINGS PER BASIC AND DILUTED SHARE, COMPARED TO ADJUSTED EARNINGS OF $47.6 MILLION AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $61.8 MILLION, OR $1.14 ADJUSTED EARNINGS PER BASIC SHARE AND $1.13 ADJUSTED EARNINGS PER DILUTED SHARE FOR THE THREE MONTHS ENDED JUNE 30, 2024.

ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025

HAMILTON, BERMUDA , JULY 16, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY PLANS TO ANNOUNCE ITS SECOND QUARTER EARNINGS BEFORE THE MARKET OPENS WEDNESDAY, JULY 30, 2025 AND WILL HOST A CONFERENCE CALL LATER IN THE DAY AT 10:00 A.M. EASTERN TIME.

ARDMORE SHIPPING ANNOUNCES SECOND QUARTER 2025 CONFERENCE CALL AND WEBCAST

- T HE PHASE I TRIAL EVALUATES THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF ASC50 FOR THE TREATMENT OF PSORIASIS. - PRECLINICAL DATA, INCLUDING HIGHER ORAL EXPOSURE, LONGER HALF-LIFE AND STRONG EFFICACY, SUPPORT ASC50 AS A POTENTIAL BEST-IN-CLASS ONCE-DAILY ORAL AGENT FOR THE TREATMENT OF PSORIASIS.

ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN U.S. PHASE I CLINICAL STUDY OF ASC50, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE IL-17 INHIBITOR FOR THE TREATMENT OF PSORIASIS

HONG KONG , JUNE 8, 2025 /PRNEWSWIRE/ -- ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES THAT POSTER PRESENTATIONS ON PRELIMINARY STUDIES OF ITS ORAL SMALL MOLECULE GLP-1 RECEPTOR (GLP-1R) AGONIST ASC30 AND ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE ASC47 WILL BE PRESENTED AT THE 85TH SCIENTIFIC SESSIONS OF AMERICAN DIABETES ASSOCIATION (ADA) IN CHICAGO, U.S. DETAILS OF THE POSTER PRESENTATIONS POSTER NUMBER: 750-P ABSTRACT TITLE: ASC30, AN ORAL GLP-1R BIASED SMALL MOLECULE AGONIST IN PARTICIPANTS WITH OBESITYA FIRST-IN-HUMAN SINGLE ASCENDING DOSE STUDY SESSION TYPE: GENERAL POSTER SESSION LOCATION: POSTER HALL (HALL F1) PRESENTATION TIME: SUNDAY JUN 22, 2025 12:30 PM - 1:30 PM (CHICAGO TIME), I.E., MONDAY JUN 23, 2025 1:30 AM - 2:30 AM (BEIJING TIME) POSTER NUMBER: 847-P ABSTRACT TITLE: ASC47, A MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR OBESITY, IN COMBINATION WITH SEMAGLUTIDE, DEMONSTRATED SUPERIOR WEIGHT LOSS TO SEMAGLUTIDE MONOTHERAPY IN A PRECLINICAL MODEL SESSION TYPE: GENERAL POSTER SESSION LOCATION: POSTER HALL (HALL F1) PRESENTATION TIME: SUNDAY JUN 22, 2025 12:30 PM - 1:30 PM (CHICAGO TIME), I.E.

ASCLETIS ANNOUNCES POSTER PRESENTATIONS ON THE STUDY RESULTS OF ASC30 AND ASC47 AT THE 85TH SCIENTIFIC SESSIONS OF AMERICAN DIABETES ASSOCIATION (ADA)

DENIFANSTAT (ASC40), A ONCE-DAILY ORAL FATTY ACID SYNTHASE (FASN) INHIBITOR, DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT COMPARED TO PLACEBO IN ALL PRIMARY, KEY SECONDARY, AND SECONDARY ENDPOINTS DENIFANSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE DENIFANSTAT WAS 98% AND 178% MORE EFFECTIVE THAN U.S. FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED SARECYCLINE AND DOXYCYCLINE WITH REGARD TO PLACEBO-ADJUSTED PERCENT TREATMENT SUCCESS, RESPECTIVELY, 18.6% FOR DENIFANSTAT VERSUS 9.4% FOR SARECYCLINE, 18.6% VERSUS 6.7% FOR DOXYCYCLINE DENIFANSTAT WAS 60% MORE EFFECTIVE THAN FDA-APPROVED CLASCOTERONE CREAM WITH REGARD TO PLACEBO-ADJUSTED PERCENT TREATMENT SUCCESS, 18.6% FOR DENIFANSTAT VERSUS 11.6% FOR CLASCOTERONE CREAM, RESPECTIVELY THE EXCEPTIONAL EFFICACY OF DENIFANSTAT COUPLED WITH ITS FAVORABLE SAFETY PROFILE IN THE PHASE III TRIAL PROVIDES A POTENTIAL MAJOR BREAK-THROUGH FOR THE TREATMENT OF ACNE HONG KONG , JUNE 3, 2025 /PRNEWSWIRE/ -- ASCLETIS PHARMA INC. (HKEX: 1672, "ASCLETIS") ANNOUNCES TODAY THAT DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL SMALL MOLECULE FATTY ACID SYNTHASE (FASN) INHIBITOR, MEETS ALL PRIMARY, KEY SECONDARY, AND SECONDARY ENDPOINTS IN THE PHASE III CLINICAL TRIAL FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS (NCT06192264). THE PHASE III CLINICAL TRIAL WAS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL TRIAL IN CHINA TO EVALUATE THE SAFETY AND EFFICACY OF DENIFANSTAT ONCE-DAILY ORAL TABLET IN 480 PATIENTS WITH MODERATE TO SEVERE ACNE VULGARIS.

ASCLETIS ANNOUNCES PHASE III TRIAL OF DENIFANSTAT (ASC40), A FIRST-IN-CLASS, ONCE-DAILY ORAL FASN INHIBITOR FOR ACNE, MEETS ALL ENDPOINTS

ASIA PACIFIC OPPORTUNITY ZONE PROJECT WAS PRESENTED TO HOUSTON MAYOR JOHN WHITMIRE AT INTERNATIONAL TRADE CENTER CONFERENCE HOUSTON, TX / ACCESS NEWSWIRE / MAY 27, 2025 / ASC GLOBAL INC. AS A WHOLLY-OWNED SUBSIDIARY OF TOKEN COMMUNITIES (OTC PINK:TKCM) PRESENTED APOZ PROJECT TO MAYOR JOHN WHITMIRE AT THE ITC ( INTERNATIONAL TRADE CENTER ) INAUGURATION CEREMONY OF THE BOARD OF DIRECTORS ON ON MAY 23, 2025. MS. TINA PEI WISE WHO IS THE DIRECTOR OF COORDINATION OF ASC GLOBAL INC. ( THE DEVELOPER OF THE APOZ PROJECT ) WAS ELECTED AS THE VICE PRESIDENT OF ITC ( INTERNATIONAL TRADE CENTER ) IN HOUSTON, TEXAS, MS.

APOZ PROJECT PRESENTED AT ITC CONFERENCE

-- ASC50 IS AN IN-HOUSE DISCOVERED AND DEVELOPED ORAL SMALL MOLECULE INTERLEUKIN-17 (IL-17) INHIBITOR FOR THE TREATMENT OF MULTIPLE AUTOIMMUNE AND INFLAMMATORY DISEASES, INCLUDING PSORIASIS . -- FOLLOWING ORAL DOSING IN NON-HUMAN PRIMATES, ASC50 DEMONSTRATED HIGHER DRUG EXPOSURE, LONGER HALF-LIFE AND LOWER CLEARANCE THAN AN ORAL SMALL MOLECULE IL-17 INHIBITOR COMPARATOR, WHICH IS CURRENTLY IN THE CLINICAL DEVELOPMENT.

ASCLETIS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ITS ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50, FOR THE TREATMENT OF PSORIASIS

HAMILTON, BERMUDA , MAY 7, 2025 /PRNEWSWIRE/ -- ARDMORE SHIPPING CORPORATION (NYSE: ASC) ("ARDMORE", THE "COMPANY" OR "WE") TODAY ANNOUNCED RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025. HIGHLIGHTS AND RECENT ACTIVITY REPORTED ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $5.6 MILLION FOR THE THREE MONTHS ENDED MARCH 31, 2025, OR $0.14 EARNINGS PER BASIC AND DILUTED SHARE, COMPARED TO ADJUSTED EARNINGS AND NET INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $38.4 MILLION, OR $0.93 EARNINGS PER BASIC SHARE AND $0.92 EARNINGS PER DILUTED SHARE FOR THE THREE MONTHS ENDED MARCH 31, 2024.

ARDMORE SHIPPING CORPORATION ANNOUNCES FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025

HONG KONG , MAY 6, 2025 /PRNEWSWIRE/ -- ASCLETIS PHARMA INC. (HKEX:1672, "ASCLETIS") ANNOUNCES ORAL AND POSTER PRESENTATIONS ON PRELIMINARY STUDIES OF ASC47, AN ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR OBESITY, WILL BE PRESENTED AT THE 32ND EUROPEAN CONGRESS ON OBESITY (ECO 2025) IN MALAGA, SPAIN. ORAL PRESENTATION DETAILS TITLE:ASC47, AN ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR OBESITY, DEMONSTRATED SIGNIFICANT WEIGHT LOSS AND PRESERVED MUSCLE IN DIO MICE ABSTRACT CATEGORY/TOPI C : OBESITY MANAGEMENT AND INTERVENTION  EMERGING TREATMENTS ABSTRACT NUMBER: 0254 SESSION: T1 ABSTRACT SESSION: NOVEL DRUGS.

ASCLETIS ANNOUNCES ORAL AND POSTER PRESENTATIONS ON ASC47, AN ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR OBESITY AT THE 32ND EUROPEAN CONGRESS ON OBESITY

ZYVERSA'S IC 100 BLOCKED MICROGLIAL NLRP1 INFLAMMASOME ACTIVATION AND REDUCED ALPHA-SYNUCLEIN ACCUMULATION SUPPORTING ITS POTENTIAL FOR PARKINSON'S DISEASE

ZYVERSA THERAPEUTICS ANNOUNCES PUBLISHED DATA SHOWING INFLAMMASOME ASC INHIBITOR IC 100 DECREASES MICROGLIAL INFLAMMASOME ACTIVATION AND ALPHA-SYNUCLEIN THAT CONTRIBUTE TO NEURODEGENERATION IN PARKINSON'S DISEASE

Ardmore Shipping Corporation

ASC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ardmore Shipping Corporation

ASC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ASC